

Group IV. Claim 22 drawn to a method of inhibiting expression of *dwf5*;

Group V. Claim 23 drawn to a method of transforming a plant with two polynucleotides;

Group VI. Claims 24-25 drawn to a method of increasing DWF5 activity;

Group VII. Claim 26 drawn to a method of modulating an endogenous DWF5 polypeptide wherein expression of a polynucleotide is inhibited;

Group VIII. Claims 27-31 drawn to a method of altering the biochemical activity of a cell;

Group IX. Claims 32-34 drawn to a method for regulating the cell cycle of a plant; and

Group X. Claim 39 drawn to a chimeric polypeptide comprising a DWF5 polypeptide and a heterologous polypeptide.


Applicants hereby elect to prosecute the claims of Group 1, claims 1-8, 10, 14-16, 18-21, without traverse. Applicants expressly reserve their right under 35 USC §121 to file one or more divisional applications directed to the nonelected subject matter during the pendency of this application.

In response to the species election requirement, applicants elect SEQ ID NOS:30 and 31, corresponding to the polynucleotide and polypeptide sequence, respectively, of *dwf5-1*. The claims reading on this species are claims

1-6, 10, 14-16 and 18-21. It is to be understood that this election of species is for the purposes of preliminary search and examination only, and that upon allowance of a generic claim, applicants will be entitled to consideration of claims to the additional species.

Respectfully submitted,

Date: 12/18/02

By:   
Roberta L. Robins  
Registration No. 33,208

ROBINS & PASTERNAK LLP  
545 Middlefield Road, Suite 180  
Menlo Park, CA 94025  
Telephone: (650) 325-7812  
Fax: (650) 325-7823